Semaglutide in Wales: NHS Access, Private Options and What to Expect

What is semaglutide, and is Wegovy the same thing people call Ozempic?

Semaglutide is the active medicine inside both Wegovy and Ozempic. The two products share the same molecule but carry different UK licences, and that distinction matters. Ozempic is authorised specifically for type 2 diabetes management. Wegovy is authorised for weight management in adults, a separate clinical programme with higher doses and a different titration path. They are not interchangeable, and a prescriber cannot legally issue Ozempic to someone whose reason for treatment is weight loss alone.

Wegovy works by activating GLP-1 receptors in the brain and gut. This slows how quickly the stomach empties, reduces appetite signals, and helps many people eat less without feeling deprived. It is given as a once-weekly subcutaneous injection, starting at a low dose that your body adjusts to before the prescriber moves you up. The NHS medicines page for semaglutide covers how the medicine works in plain language and is a useful first read.

It is worth knowing that semaglutide has also received MHRA approval for a higher 7.2 mg maintenance dose, including a dedicated single-dose pen approved in April 2026. Clinical trial data at this dose reported around 20.7% average weight loss over 72 weeks, approaching the results seen with tirzepatide at its highest strength. If you are curious whether your dosing schedule could ever be adjusted, our page on whether you can take Wegovy fortnightly explains what the evidence and licensing say. You can read more about the full Wegovy treatment picture on our Wegovy overview page.

How does NHS access to Wegovy in Wales actually work?

In England, NHS England has published a phased rollout plan tied to NICE technology appraisal TA875. Wales operates its own health system through NHS Wales, and while NICE guidance is influential, commissioning decisions sit with Local Health Boards rather than NHS England. In practice, this means the precise thresholds and service availability for Wegovy in Wales can differ, and may lag or diverge from what English patients experience.

Under NICE TA875, semaglutide for weight management is recommended only when used within a specialist weight management service offering multidisciplinary support, for a maximum of two years, in adults with a BMI of 35 or above and at least one weight-related comorbidity (such as high blood pressure, type 2 diabetes or obstructive sleep apnoea). Lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. Wales-based patients wanting to understand their current local position should speak to their GP, who can advise on what their Local Health Board is commissioning.

Waiting times through Welsh specialist services can be considerable. That reality pushes many people to look at the private route, not because it bypasses clinical rigour, but because it removes the queue. Our page on whether Wegovy is available in Wales goes into more detail on the NHS commissioning picture specifically.

What are the most common side effects of semaglutide to be aware of?

Side effects are predominantly gastrointestinal, particularly in the early weeks. Nausea is the one most people mention first. Vomiting, loose stools, constipation, reflux and indigestion also appear commonly in clinical trial data, as does fatigue. Most people find these effects are worst after a dose increase and settle within a week or two as the body adapts. The slow titration schedule exists largely for this reason: moving up gradually gives your system time to adjust.

More serious but less common effects include pancreatitis. The MHRA issued a Drug Safety Update in January 2026 reinforcing that severe, persistent stomach pain (especially pain that spreads to the back) is a reason to seek urgent medical attention and to stop treatment until a clinician has assessed you. If you experience symptoms of an allergic reaction, sudden changes in vision, or signs of gallbladder trouble, the same applies: get medical help promptly rather than waiting for your next scheduled check-in.

Yellow Card is the MHRA's reporting tool for suspected side effects. Patients and carers can submit reports directly at yellowcard.mhra.gov.uk, a step that contributes to ongoing medicines safety surveillance. Semaglutide carries a Black Triangle (▼) designation, meaning it is under additional monitoring while real-world safety data continues to accumulate. More detail on what to watch for is covered on our semaglutide information page.

What does getting semaglutide privately through a UK pharmacy actually involve?

The process through a registered private pharmacy starts with a clinical consultation, not a checkout. At nume, a GPhC-registered Independent Prescriber reads your answers personally (a real clinician, not a triage algorithm) typically the same day you submit. Identity is verified, weight is confirmed on video, and your medical history is reviewed against the licensed eligibility criteria before any prescription is written.

If the prescriber determines semaglutide is clinically appropriate, the prescription is dispensed from our own GPhC-registered pharmacy (registration number 9012878, verifiable on the GPhC register). Your treatment arrives via DPD the next working day, tracked to your door, in plain unbranded packaging, the pen itself is a pre-filled injector, discreet and straightforward to use once your prescriber has walked you through the technique.

One price covers the consultation, prescription, treatment and delivery. There are no subscription commitments, and every repeat order goes through the same clinical re-review rather than being dispatched automatically. For context on how the wider market for this medicine has shifted, our page tracking semaglutide sales across the UK sets out the data behind growing demand. For a full picture of what private treatment costs and what those costs include, our Wegovy pricing page sets that out clearly. If you'd like to explore whether you might be eligible, our weight-loss treatments overview is a useful starting point before you consult.